|
|
||||||||||
|
J Am Coll Cardiol, 1992; 19:1597-1600 © 1992 by the American College of Cardiology Foundation |
Mid America Heart Institute, St. Luke's Hospital, Kansas City, Missouri.
Colchicine, an antimitogenic agent, has shown promise in preventing restenosis after coronary angioplasty in experimental animal models. A prospective trial was conducted involving 197 patients randomized in a 2:1 fashion to treatment with oral colchicine, 0.6 mg twice daily (130 patients), or placebo (67 patients) for 6 months after elective coronary angioplasty. Treatment in all patients began between 12 h before angioplasty and 24 h after angioplasty. Compliance monitoring revealed that 96% of all prescribed pills were ingested. Demographic characteristics were similar in colchicine- and placebo-treated groups. A mean of 2.7 lesions/patient were dilated. Side effects resulted in a 6.9% dropout rate in the colchicine-treated patients. Complete quantitative angiographic follow-up was obtained in 145 patients (74%) with 393 dilated lesions. Quantitative angiographic measurements were obtained in two orthogonal views at baseline before angioplasty and immediately and at 6 months after angioplasty. The quantitative mean lumen diameter stenosis before angioplasty was 67% both in the 152 lesions in the placebo-treated group and in the 241 lesions in the colchicine-treated group; this value was reduced to 24% immediately after angioplasty in the lesions in both treatment groups. At the 6-month angiogram, lesions had restenosed to 47% lumen diameter narrowing in the placebo-treated group compared with 46% in the colchicine-treated group (p = NS). Forty-one percent of colchicine-treated patients developed restenosis in at least one lesion compared with 45% of the placebo-treated group (p = NS). In conclusion, colchicine was ineffective for preventing restenosis after coronary angioplasty.
This article has been cited by other articles:
![]() |
S. C. Smith Jr, J. T. Dove, A. K. Jacobs, J. Ward Kennedy, D. Kereiakes, M. J. Kern, R. E. Kuntz, J. J. Popma, H. V. Schaff, D. O. Williams, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2239 - 2239. [Full Text] [PDF] |
||||
![]() |
A. M. Miller, A. R. McPhaden, R. M. Wadsworth, and C. L. Wainwright Inhibition by leukocyte depletion of neointima formation after balloon angioplasty in a rabbit model of restenosis Cardiovasc Res, March 1, 2001; 49(4): 838 - 850. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. D. Kolodgie, A. Farb, and R. Virmani Local Delivery of Ceramide for Restenosis : Is There a Future for Lipid Therapy? Circ. Res., August 18, 2000; 87(4): 264 - 267. [Full Text] [PDF] |
||||
![]() |
M. Gottsauner-Wolf, G. Zasmeta, S. Hornykewycz, M. Nikfardjam, E. Stepan, P. Wexberg, G. Zorn, D. Glogar, P. Probst, G. Maurer, et al. Plasma levels of C-reactive protein after coronary stent implantation Eur. Heart J., July 2, 2000; 21(14): 1152 - 1158. [Abstract] [PDF] |
||||
![]() |
C. Herdeg, M. Oberhoff, A. Baumbach, A. Blattner, D. I. Axel, S. Schroder, H. Heinle, and K. R. Karsch Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1969 - 1976. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Lansky, G. S. Mintz, J. J. Popma, A. D. Pichard, K. M. Kent, L. F. Satler, D. S. Baim, R. E. Kuntz, C. Simonton, R. M. Bersin, et al. Remodeling after directional coronary atherectomy (with and without adjunct percutaneous transluminal coronary angioplasty): a serial angiographic and intravascular ultrasound analysis from the optimal atherectomy restenosis study J. Am. Coll. Cardiol., August 1, 1998; 32(2): 329 - 337. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Jenkins, M. T. Crow, C. Bilato, Y. Gluzband, W.-S. Ryu, Z. Li, W. Stetler-Stevenson, C. Nater, J. P. Froehlich, E. G. Lakatta, et al. Increased Expression of Membrane-Type Matrix Metalloproteinase and Preferential Localization of Matrix Metalloproteinase-2 to the Neointima of Balloon-Injured Rat Carotid Arteries Circulation, January 13, 1998; 97(1): 82 - 90. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Guzman, V. Labhasetwar, C. Song, Y. Jang, A. M. Lincoff, R. Levy, and E. J. Topol Local Intraluminal Infusion of Biodegradable Polymeric Nanoparticles: A Novel Approach for Prolonged Drug Delivery After Balloon Angioplasty Circulation, September 15, 1996; 94(6): 1441 - 1448. [Abstract] [Full Text] |
||||
![]() |
G. S. Mintz, J. J. Popma, A. D. Pichard, K. M. Kent, L. F. Satler, S. Chiu Wong, M. K. Hong, J. A. Kovach, and M. B. Leon Arterial Remodeling After Coronary Angioplasty : A Serial Intravascular Ultrasound Study Circulation, July 1, 1996; 94(1): 35 - 43. [Abstract] [Full Text] |
||||
![]() |
L. A. Guzman, M. J. Mick, A. M. Arnold, F. Forudi, and P. L. Whitlow Role of Intimal Hyperplasia and Arterial Remodeling After Balloon Angioplasty : An Experimental Study in the Atherosclerotic Rabbit Model Arterioscler. Thromb. Vasc. Biol., March 1, 1996; 16(3): 479 - 487. [Abstract] [Full Text] |
||||
![]() |
C. Rogers and E. R. Edelman Endovascular Stent Design Dictates Experimental Restenosis and Thrombosis Circulation, June 15, 1995; 91(12): 2995 - 3001. [Abstract] [Full Text] |
||||
![]() |
T Ohno, D Gordon, H San, V. Pompili, M. Imperiale, G. Nabel, and E. Nabel Gene therapy for vascular smooth muscle cell proliferation after arterial injury Science, August 5, 1994; 265(5173): 781 - 784. [Abstract] [PDF] |
||||
![]() |
C. Landau, R. A. Lange, and L. D. Hillis Percutaneous Transluminal Coronary Angioplasty N. Engl. J. Med., April 7, 1994; 330(14): 981 - 993. [Full Text] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |